- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07926269
Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Lower Abdominal Surgery
Analgesic Efficacy of Posterior Versus Transmuscular Quadratus Lumborum Block in Children Undergoing Unilateral Lower Abdominal Surgery: A Randomized Controlled Trial
The quadratus lumborum block (QLB) is an established regional anesthesia technique that provides somatic and visceral analgesia for abdominal wall procedures in both adult and pediatric populations. Among its standardized approaches, the posterior QLB (QL2-injectate deposited in the lumbar interfascial triangle at the posterior surface of the quadratus lumborum muscle) and the transmuscular QLB (QL3-injectate deposited in the fascial plane between the anterior surface of the quadratus lumborum and psoas major muscles) are widely utilized.
Although cadaveric and radiological studies suggest that transmuscular QLB yields greater anterior and thoracic paravertebral spread compared to the posterior approach, comparative clinical evidence in pediatric populations remains limited.
The objective of this randomized, prospective, double-blind controlled trial is to compare the analgesic efficacy of ultrasound-guided posterior QLB (QL2) versus transmuscular QLB (QL3) using an identical weight-based dose and concentration of local anesthetic (0.4 mL/kg of bupivacaine 0.25%) in children aged 1 to 7 years undergoing elective unilateral lower abdominal surgery (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy). The primary hypothesis is that one approach will provide superior 24-hour cumulative opioid-sparing analgesia compared to the other.
Study Overview
Status
Detailed Description
Background and Anatomical Rationale:
Truncal fascial plane blocks like the quadratus lumborum block (QLB) play a key role in pediatric multimodal analgesia. While posterior QLB (QL2) targets the lumbar interfascial triangle (LIFT) with minimal anatomical risk to deep structures, transmuscular QLB (QL3) penetrates the QL muscle to deposit local anesthetic in the anterior fascial plane adjacent to the psoas major muscle. This study evaluates whether these anatomical differences translate into distinct clinical analgesic outcomes in pediatric patients.
Anesthetic Protocol and Block Execution:
Following standardized general anesthesia induction and airway securing, children assigned to either group receive an ultrasound-guided unilateral block in the lateral decubitus position using the classic "Shamrock" sonographic landmark view (L3 transverse process level).
Posterior QLB Group (QL2): A short-bevel echogenic needle is advanced in-plane to the posterior aspect of the quadratus lumborum muscle (QLM) within the lumbar interfascial triangle.
Transmuscular QLB Group (QL3): An identical needle is advanced transmuscularly through the QLM into the fascial plane between the anterior surface of the QL and psoas major muscle.
In both groups, plane identification is confirmed by hydrodissection (1-2 mL saline/D5W), followed by slow injection of 0.4 mL/kg bupivacaine 0.25% (1 mg/kg; maximum 20 mL) with intermittent aspiration every 3-5 mL.
Postoperative Analgesic Management and Assessment:
Postoperative behavioral pain intensity is monitored by a blinded observer using the Face, Legs, Activity, Cry, Consolability (FLACC) score at 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively. Stepwise rescue analgesia is initiated for FLACC scores ≥4: intravenous paracetamol 15 mg/kg (if >6 hours from prior dose), followed by rescue intravenous fentanyl 0.5 µg/kg or morphine 0.05 mg/kg if pain persists.
Sedation (University of Michigan Sedation Scale), motor block (modified Bromage scale), time to first rescue request, incidence of postoperative nausea and vomiting (PONV), parental satisfaction (5-point Likert scale), and time to post-anesthesia discharge readiness are systematically evaluated.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kerollos Moneer Neseem Mikhael, MD
- Phone Number: 00201288549959
- Email: Kmnmk87@med.bsu.edu.eg
Study Locations
-
-
-
Banī Suwayf, Egypt
- Beni-Suef University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Children aged 1 to 7 years. American Society of Anesthesiologists (ASA) physical status I or II. Scheduled for elective unilateral lower abdominal surgery under general anesthesia with a planned quadratus lumborum block for postoperative analgesia (e.g., inguinal herniotomy, orchiopexy, hydrocelectomy).
Written informed consent obtained from a parent or legal guardian.
Exclusion Criteria:
Parental or guardian refusal to participate. Known allergy or hypersensitivity to amide local anesthetics. Coagulopathy or active use of anticoagulant or antiplatelet medication. Local skin infection at the intended regional block injection site. Planned bilateral surgical procedure. Significant hepatic, renal, cardiac, or neuromuscular disease. Developmental delay or medical condition precluding reliable pain-scale assessment.
Preoperative chronic opioid or regular analgesic use. Body weight below the 3rd percentile for age, or known spinal/vertebral column anomaly precluding safe block performance.
Emergency surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Posterior QLB (QL2)
Children assigned to this arm receive a single-dose, ultrasound-guided posterior quadratus lumborum block (QL2) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance, a short-bevel echogenic needle is advanced to the posterior surface of the quadratus lumborum muscle within the lumbar interfascial triangle (LIFT). Local anesthetic is deposited following hydrodissection confirmation and negative aspiration. |
Ultrasound-guided single-injection posterior quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited at the posterior border of the QL muscle within the lumbar interfascial triangle.
Other Names:
|
|
Active Comparator: Transmuscular QLB (QL3)
Children assigned to this arm receive a single-dose, ultrasound-guided transmuscular quadratus lumborum block (QL3) performed after induction of general anesthesia and prior to surgical incision. Under ultrasound guidance using the "Shamrock" view, a short-bevel needle is advanced transmuscularly through the quadratus lumborum muscle to deposit local anesthetic in the fascial plane between its anterior surface and the psoas major muscle following hydrodissection confirmation and negative aspiration. |
Ultrasound-guided single-injection transmuscular quadratus lumborum block performed pre-incisions under general anesthesia. Local anesthetic: 0.4 mL/kg of bupivacaine 0.25% (1 mg/kg; maximum single-side volume 20 mL) deposited in the plane between the anterior surface of the QL muscle and psoas major muscle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Cumulative Opioid Consumption in the First 24 Hours
Time Frame: First 24 hours postoperatively
|
Total cumulative dose of intraoperative and postoperative rescue opioids administered during the first 24 hours postoperatively, converted to intravenous morphine-equivalent doses (mg/kg) using standard conversion ratios and normalized to body weight. A lower numerical value indicates a superior clinical outcome (greater opioid-sparing effect and reduced opioid requirement). |
First 24 hours postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative Pain Intensity Scores
Time Frame: At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Postoperative pain intensity measured using the Face, Legs, Activity, Cry, Consolability (FLACC) behavioral pain scale. Scores range from 0 to 10, where 0 represents no pain (relaxed and comfortable; best outcome) and 10 represents severe pain/discomfort (worst outcome). Lower numerical scores represent better pain control. |
At 0 (PACU arrival), 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Time to First Rescue Analgesia Request
Time Frame: Up to 24 hours postoperatively
|
Time elapsed (in minutes) from arrival in the Post-Anesthesia Care Unit (PACU) until the first administration of rescue analgesic (triggered by a FLACC score ≥4). A higher numerical value (longer duration of time) indicates a superior clinical outcome (prolonged block duration and delayed pain onset). |
Up to 24 hours postoperatively
|
|
Block Execution Time
Time Frame: Intraoperatively (during block performance)
|
Total time required to perform the ultrasound-guided regional block, measured in seconds from initial placement of the ultrasound transducer on the skin to needle withdrawal. Lower execution times represent greater technical ease and efficiency (better procedural performance). |
Intraoperatively (during block performance)
|
|
Number of Needle Passes and Redirections
Time Frame: Intraoperatively (during block performance)
|
Number of discrete needle skin punctures and forward redirections required to achieve correct needle tip positioning within the intended target fascial plane. A lower count indicates easier needle placement and less tissue trauma (better procedural outcome). |
Intraoperatively (during block performance)
|
|
Incidence and Severity of Postoperative Nausea and Vomiting
Time Frame: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Presence and severity of postoperative nausea and vomiting assessed using a 4-point scale (0 = no nausea or vomiting [best outcome], 1 = mild nausea, 2 = moderate nausea or single emetic episode, 3 = severe nausea or multiple emetic episodes requiring antiemetic rescue [worst outcome]). Lower scores represent a better clinical outcome. |
At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Postoperative Sedation Score
Time Frame: At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
Sedation level evaluated using the University of Michigan Sedation Scale (UMSS), ranging from 0 (awake and alert; normal state) to 4 (unarousable to noxious stimuli; severe sedation/respiratory risk). Lower scores (specifically 0 to 1) represent desirable postoperative alertness and faster recovery. |
At 0, 1, 2, 4, 6, 12, 18, and 24 hours postoperatively
|
|
Incidence and Degree of Lower Limb Motor Blockade
Time Frame: At 1, 4, and 8 hours postoperatively
|
Motor weakness evaluated using a modified Bromage scale (0 = full flexion of knees and feet / no motor block [best safety outcome], 1 = partial flexion, 2 = movement of feet only, 3 = complete paralysis of lower limb [worst outcome]). A score of 0 indicates an optimal motor-sparing sensory block without unwanted lumbar plexus involvement. |
At 1, 4, and 8 hours postoperatively
|
|
Parental Satisfaction Score
Time Frame: 24 hours postoperatively
|
Parental or legal guardian overall satisfaction with post-surgical pain management evaluated on a 5-point Likert scale (1 = very dissatisfied [worst outcome], 2 = dissatisfied, 3 = neutral, 4 = satisfied, 5 = very satisfied [best outcome]). Higher numerical scores represent a superior clinical outcome. |
24 hours postoperatively
|
|
Time to Post-Anesthesia Discharge Readiness
Time Frame: Up to 24 hours postoperatively
|
Time elapsed (in minutes) from PACU arrival until the child satisfies all criteria of the modified pediatric Post-Anesthesia Discharge Scoring System (PADSS). A lower numerical value (shorter duration of time in minutes) indicates a better outcome (faster recovery and earlier discharge readiness). |
Up to 24 hours postoperatively
|
|
Incidence of Block-Related Adverse Events and Complications
Time Frame: Through 24 hours postoperatively
|
Total count and percentage of procedural complications (including vascular puncture, LAST, peritoneal injury, localized hematoma, or infection). A lower number (ideally 0) indicates a superior safety profile. |
Through 24 hours postoperatively
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pain
- Neurologic Manifestations
- Endocrine System Diseases
- Postoperative Complications
- Pathologic Processes
- Genital Diseases, Male
- Male Urogenital Diseases
- Pathological Conditions, Anatomical
- Gonadal Disorders
- Congenital Abnormalities
- Hernia
- Urogenital Abnormalities
- Hernia, Abdominal
- Testicular Diseases
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Pain, Postoperative
- Hernia, Inguinal
- Cryptorchidism
- Testicular Hydrocele
Other Study ID Numbers
- FMBSUREC/08092026b/ Mikhael
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data (including primary outcome measures, demographic variables, FLACC pain scores, cumulative opioid consumption, and block execution metrics) will be made available to qualified academic researchers upon reasonable request submitted to the principal investigator, following publication of the primary trial results.
IPD Sharing Time Frame
Data will become available 3 months following peer-reviewed journal publication of the primary manuscript and will remain accessible for 3 years.
IPD Sharing Access Criteria
Data will be shared with recognized medical and academic researchers who submit a sound scientific proposal and a signed data-use agreement to the principal investigator (at Kmnmk87@med.bsu.edu.eg).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.